After exciting results with skin and lung cancer, the government approved the marketing of immunotherapy drug Opdivo for kidney cancer. Professor Michael Boyer, Lifehouse’s Chief Clinical Officer, says: “Tumours develop a way of evading our immune system and making themselves invisible. What these drugs do is allow the immune system to once again see.”
The drug is currently under review for listing under the pharmaceutical benefits scheme, making it affordable for patients.
View the news story here.